NCT06566443 is a Phase 1 clinical trial of Honokiol in Carcinoma, Non-Small-Cell Lung, sponsored by The Methodist Hospital Research Institute.

Who is sponsoring NCT06566443?

NCT06566443 is sponsored by The Methodist Hospital Research Institute.

What drugs are being tested in NCT06566443?

Interventions in NCT06566443: Honokiol.

What condition does NCT06566443 study?

NCT06566443 studies Carcinoma, Non-Small-Cell Lung.

Is NCT06566443 still recruiting?

NCT06566443 is currently recruiting now. Last updated 26 May 2026.

Last reviewed 2026-05-26 · How we verify

NCT06566443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Recruiting now Phase 1 Last updated 26 May 2026

What this trial tests

Phase 1 trial testing Honokiol in Carcinoma, Non-Small-Cell Lung in 15 participants. Currently enrolling.

Timeline

13 February 2025

Primary endpoint
1 August 2026

1 August 2027

Quick facts

Lead sponsor	The Methodist Hospital Research Institute
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	15
Start date	13 February 2025
Primary completion	1 August 2026
Estimated completion	1 August 2027
Sites	1 location across United States

Drugs / interventions tested

Honokiol — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

The Methodist Hospital Research Institute

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum Tolerated Dose of Honokiol therapy
Time frame: From treatment initiation of each patient, assessed up to 21 days after treatment initiation of final patient, up to 2 years after first enrollment.
To determine the maximum tolerated dose (MTD) of honokiol therapy in patients with stage I NSCLC, less than 4 cm, who will undergo surgical resection. Review the safety data to determine the dose level at which the maximum tolerable level of toxicity is observed and select as the MTD the dose for which the isotonic estimate of the DLT rate is closest to the target DLT rate.

Sponsor's own description

This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study. The study will only enroll patients with stage I lung cancers less than 4 cm, given the recent approval of neoadjuvant chemotherapy and nivolumab for stage IB tumors \> 4 cm. Approximately, 15 patients will be enrolled in the study. They will take the study drug, honokiol, for 2 weeks prior to the surgery. The primary endpoint will be the Maximum Tolerated Dose (MTD) of honokiol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other The Methodist Hospital Research Institute trials

Trials by the same sponsor.

NCT07048314 — Stem Cells for Erectile Dysfunction Post RALP · Phase 1, PHASE2 · not yet recruiting
NCT07283068 — IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA · NA · not yet recruiting
NCT07218484 — VoiceLove Digital Therapy for Delirium in the ICU · NA · recruiting
NCT07050771 — Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery · Phase 2 · recruiting
NCT07182279 — Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06566443 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Methodist Hospital Research Institute
Last refreshed: 26 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06566443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing